Using the murine Hepa 1–6 and BNL HCC tumor models along with the highly aggressive CT26 colorectal tumor model, we determined that entolimod’s protective activity against TNF toxicity is limited to normal tissues (not tumors), even with D-GalN sensitization. Here, TNF is linked to colorectal neoplasm.